Mass Spectrometry

Latest News

Best of the Week: Recapping Analytica 2024
Best of the Week: Recapping Analytica 2024

April 12th 2024

Here are the top five articles that the editors of Spectroscopy published this week.

Cell viability assay by 96 well micro plate for Drug screening | Image Credit: © HYUNGKEUN - stock.adobe.com
NIR Tested for Drug Screening Capabilities

March 29th 2024

Top stories symbol. Concept words Top stories on wooden blocks on a beautiful blue table white background. Business story and top stories concept, copy space. | Image Credit: © Dzmitry - stock.adobe.com
Best of the Week: Analyzing Mummy Hair, A Conversation with PerkinElmer

March 15th 2024

Image Credit: © Oligo Factory
Synthesizing Synthetic Oligonucleotides: An Interview with the CEO of Oligo Factory

February 6th 2024

Potassium. Kalium. Alkali metals. Chemical Element of Mendeleev's Periodic Table. Potassium in square cube creative concept. | Image Credit: © Aleksander - stock.adobe.com
Potassium Isotopic Composition in Plants Analyzed Using MC-ICP-MS

December 12th 2023

More News


Marzilli-fig05_web.jpg

Minimizing Method-Induced Deamidation and Isomerization During Antibody Characterization to Ensure Optimal Understanding of Product Quality Attributes

March 1st 2017

Accurate evaluation of chemical modifications such as asparagine deamidation and aspartic acid isomerization is an essential component of comprehensive characterization of therapeutic monoclonal antibodies (mAbs). When located in the complementarity determining regions (CDRs), these modifications can cause a loss of function, impacting product efficacy and safety, resulting in the designation of the modification as a critical quality attribute. However, artifactual modifications can be introduced by analytical procedures, and distinguishing modifications as either critical quality attributes or method-induced artifacts is an important objective for product development. Conventional peptide mapping coupled with ultrahigh-resolution mass spectrometry offers advanced capabilities for definitive characterization of protein therapeutics. However, experimental conditions such as digestion time and pH can influence the observed level of chemical modifications, usually leading to over-estimation. In this work, a new peptide mapping method was developed specifically for mAb characterization that employs optimal enzyme pH for robustness, but short digestion times and time-course elements to minimize and monitor deamidation/isomerization, respectively, allowing a more accurate assessment of potential CDR sequence liabilities.


table2-web.jpg

The Role of Liquid Chromatography–Mass Spectrometry in the Characterization of Therapeutic Monoclonal Antibodies

May 1st 2016

Monoclonal antibodies (mAbs) have been increasingly used as biotherapeutic agents and a number of new mAbs are currently in the drug pipeline. Over the next five years the patent on at least nine major biotherapeutic monoclonal antibodies will expire, opening the door for development and marketing of generic forms known as Biosimilars. In this paper a review of the central role mass spectrometry coupled to liquid chromatography plays in characterizing these antibodies is presented. Contemporary top down and middle-up approaches using mass spectrometry and various novel separation techniques to measure the intact masses of mAbs and their subunits or domains are highlighted. Example data of an innovator mAb, Humira (adalimumab) are presented showing the identities and relative abundances of the isoforms associated with this mAb. Similarly the current state of classical peptide mapping using reversed-phase chromatography and tandem mass spectrometry with scan- dependent acquisition is briefly reviewed. Novel approaches that speed analysis and provide information on post translational modifications, glycosylation, and disulfide mapping are discussed. Example data of stressed and unstressed samples of adalimumab are also presented to demonstrate peptide mapping data and modifications to the antibody. Lastly, the current use of mass spectrometry in glycoprofiling of mAbs is reviewed. Example glycan data for adalimumab generated by a novel labeling scheme and sensitive to detection by both fluorescence and mass spectrometry will be presented.